Background: Carbamazepine (CBZ) occasionally causes haematological disorders such as thrombocytopenia, and recently a case of oxcarbazepine (OXCBZ)-induced thrombocytopenia has been described. The aim of our study was blood platelet count determination in epileptic patients treated with CBZ and OXCBZ, and its relationship with the dose and serum levels of these drugs and its metabolites.
INTRODUCTION
Oxcarbazepine (Trileptal ® , OXCBZ) is an antiepileptic drug used for the treatment of partial seizures, which has been developed through the structural modifi cation of carbamazepine (Tegretol ® , CBZ) with the aim of avoiding metabolites causing side eff ects. There are diff erences between both drugs in their metabolisation, way of acting, effi cacy and tolerability, with OXCBZ off ering a number of clinically relevant advantages 1 . CBZ is metabolised to carbamazepine-10,11-epoxide (CBZE), and subsequently transformed into trans-10,11-dihydrocarbamazepine, with the pharmacological activity and proposed action mechanism of CBZE similar to that of the parent drug. In humans, OXCBZ is almost completely metabolised by reduction to its pharmacologically active monohydroxy derivative (10-hydroxycarbazepine, MHCBZ) 1 . Unlike CBZ, phenobarbital or phenytoin, the OXCBZ metabolism is not induced or inhibited via cytochrome P-450, because the formation of MHCBZ from the parent drug occurs through a reduction of the carbonyl group by means a nonmicrosomal and noninducible ketoreductase 1 ; however, OXCBZ has a signifi cant inducing eff ect on the cytochrome system, although it is about 46 % lower than that of CBZ 2 . CBZ occasionally causes thrombocytopenia with generalized petechiae and ecchymoses, which most frequently appear 2 weeks after starting treatment [3] [4] [5] , although some cases are asymptomatic and unexpectedly found by routine laboratory testing 6, 7 ; however, the pathophysiological mechanism is not well understood 3 . A decrease in blood platelets is not considered a major side eff ect of OXCBZ 8 ; nevertheless, Mahmud et al. 9 recently described a case of thrombocytopenia secondary to OXCBZ administration, and these authors recommend that physicians prescribing this drug should carry out blood-profi le monitoring for the patients treated.
The aim of our study was to compare the blood platelet count, mean platelet volume (MPV), and platelet size distribution width (PDW) in epileptic patients submitted to us for therapeutic drug monitoring of CBZ and OXCBZ, and the relation between daily dose of these drugs and serum levels of CBZ, CBZE, and MHCBZ.
PATIENTS AND METHODS
A group of 197 ambulatory epileptic patients (106 males and 91 females) with a mean age (±SEM) of 35.3 ± 1.6 years (range 3-88 years), none of whom had epilepsy secondary to ischemic head stroke, took part in this study. 137 cases were treated with CBZ in monotherapy (n = 97) and polytherapy (n = 40), and in 60 cases with OXCZ in monotherapy (n = 50) and polytherapy (n = 10). In the cases in polytherapy, the concomitantly administered antiepileptic drugs were phenytoin and valproic acid. Daily drug administration was always given in multiple doses, and blood samples were taken at least after a 3 month period without any modifi cation of the dosage, and immediately before the fi rst corresponding daily dose. As a result, the CBZ, CBZE and MHCBZ serum concentrations correspond to the steady-state trough levels.
The serum levels of CBZ, CBZE, OXCBZ and MHCBZ were determined using an Agilent 1100 Series Chromatographic System (Waldbronn, Germany) with reagents and procedures provided by Chromsystems Instruments and Chemicals GmbH (Munich, Germany). The assays were carried out using an isocratic system with UV detection at 204 nm, a detection limit of approximately 0.5 mg/l, and intra-and inter-assay variation coeffi cients of less than 6 %. Serum samples were stored for less than 7 days at -25 °C, conditions that provide adequate stability for the parent drugs and metabolites assayed 10, 11 . The platelet count and the MPV and PDW platelet indices were measured in blood samples collected 2-3 hours beforehand in K 3 EDTA anticoagulated tubes (BD Vacutainer, Plymouth, UK), using an Advia 120 Hematology System (Bayer Corporation,Tarrytown, NY, USA).
Statistical analysis of the data was performed using the Microsoft-Excel package, and the Kolmogorov-Smirnov test was applied to check for normality. Pearson's correlation coeffi cient was used when the data had a Gaussian distribution. Otherwise, Spearman's correlation coefficient was used. The results were expressed as mean ±SEM (median).
RESULTS
The 137 patients treated with CBZ, for a dose of 757.14 ± 24.28 mg/day (range 300-1200 mg/day) had a serum level for the parent drug of 7.63 ± 0.23 mg/l (range 2.4-18.9 mg/l), and CBZE of 2.34 ± 0.12 mg/l (range 0.0-9.8 mg/l). In the case of the 60 patients treated with OXCBZ, for a dose of 1167.27 ± 57.03 mg/day (range 300-1800 mg/day), the serum concentration of MHCBZ was 16.47 ± 0.80 mg/l (range 3.6-32.7 mg/l). Detectable levels of unmetabolized OXCBZ were found in only two cases.
The distribution of the platelet count in the patients treated with CBZ and OXCBZ is shown in Fig. 1 , without fi nding any signifi cant diff erences between the groups of patients for the platelet count (265.34 ± 6.96 x 10 9 /l vs 252.1 ± 9.78 x 10 9 /l), VPM (7.95 ± 0.09 fl vs 7.99 ± 0.12 fl) or PDW (49.92 ± 0.68 % vs 49.56 ± 1.15 %). Neither did the administration in mono-or polytherapy of CBZ or OXCBZ introduce an additional variation factor (Fig. 1) . Statistically signifi cant negative correlations were found for the platelet count with the daily doses of CBZ and OXCBZ, but not with the serum levels of these drugs or their metabolites, as shown in Table 1 . In the partial correlation between CBZ dose and platelet count, keeping VPM constant, the statistical signifi cance was also achieved (p < 0.05). Considering only the cases treated in monotherapy led to a slight improvement in the correlation coeffi cient for the platelet count with the OXCBZ dose (r = -0.319, p < 0.01), although not with that of CBZ (r = -0.256, p < 0.01).
In our study, thrombocytopenia was defi ned as a platelet count lesser than 150 x 10 9 /l. Four patients (2 male Signifi cance : * p < 0.05; ** p < 0.01 Relation of blood platelet count during carbamazepine and oxcarbazepine treatment with daily dose, and serum concentrations of carbamazepine, carbamazepine-10,11-epoxide, and 10-hydroxycarbazepine and 2 female) with a mean age of 60.5 ± 11.5 years (range 30-83 years) treated with CBZ and a female of 27 years treated with OXCBZ had thrombocytopenia, with a platelet count of 125 ± 6.29 x 10 9 /l (range 112-148 x 10 9 /l), VPM of 9.72 ± 0.47 fl (range 8.1-11.0 fl) and PDW of 61.08 ± 7.06 % (range 44.9-83.8 %). In accordance with previously published data on the possible discrimination of hypo-productive or hyper-destructive thrombocytopenia using these platelet indices 12, 13 , in the 5 epileptic patients with decreased platelet count, this fact may be due to a hyper-destruction of peripheral blood platelets. Furthermore, the calculation of the residual PDW according to Osselaer et al. 14 in the 8 patients with a platelet count greater than 400 x 10 9 /l, suggests that in at least 7 of the cases, discrete thombocytosis (466 ± 27 x 10 9 /l) was secondary or reactive.
DISCUSSION
The pathophysiological mechanism of CBZ-induced thrombocytopenia has not been fi rmly established, and further studies are required 3 . An immune mechanism has been proposed, with an antibody-mediated destruction of platelets in peripheral blood in the absence of bone marrow suppression 15 . Anti-IgG CBZ-dependent platelet reactive antibodies have been identifi ed in blood 6, 17 ; however, no plasma antibodies against platelet GP IIb/ IIIa or Ib in the presence or absence of CBZ were found in another study, without any defi nitive evidence for an immune-mediated-mechanism 3 . In one patient who developed thrombocytopenia during CBZ treatment, the lymphocyte stimulation test with CBZE was positive, but not with CBZ, suggesting that this CBZ metabolite was the compound involved in the pathogenesis of the CBZinduced thrombocytopenia 4 . With regard to the possible eff ect of administering OXCBZ on the platelet number, this has been studied in much less detail, and only recently has one case of OXCBZ-induced thrombocytopenia been described 9 . Adverse drug reactions may be generally separated into drug-induced diseases and dose-related toxicity, the latter being far more common 18 . Our study did not reveal any signifi cant relationship between the platelet count and serum concentrations of CBZ, CBZE or MHCBZ, suggesting that CBZ or OXCBZ-induced thrombocytopenia is not mediated by direct toxicity of these drugs or its metabolites on the circulating platelets. Similar results have been described for hematotoxicity induced by other drugs such as clozapine 19 . However, in the epileptic patients studied, a weak but signifi cant negative correlation was obtained between the platelet count and the daily doses of CBZ and OXCBZ.
In previous studies, some asymptomatic cases of thrombocytopenia in patients treated with CBZ were unexpectedly found by routine laboratory testing 6, 7 . For the total number of patients studied, in 184 cases (93 %) the number of platelets was within the reference range (150-400 x 10 9 /l), with mean values for the platelet count (255.21 ± 4.52 x 10 9 /l), VPM (7.95 ± 0.07 fl) and PDW (49.52 ± 0.55 %) similar to those found in control subjects 20 . In the 5 patients we found with thrombocytopenia (4 treated with CBZ and 1 with OXCBZ), the results obtained for the platelet indices VPM and RDW 12, 13 suggest a hyper-destruction and reduced blood platelet survival similar to that seen in immune thrombocytopenia. Although the patients treated with OXCBZ shown a lower prevalence for thrombocytopenia (1.7 %) than those treated with CBZ (2.9 %), the confi rmation of this subject in a greater number of patients appears mandatory.
As regards the 8 patients with a platelet count greater than 400x10 9 /l (7 treated with CBZ and 1 with OXCBZ), calculating the residual PDW 14 suggests that the discrete thrombocytosis found would be of the reactive type. In accordance with previously published results, the CBZ may cause an infl ammatory reaction within hours, with increased levels of serum interleukin-6 3 . Reactive thrombocytosis may result from an increase in interleukin-6, and it has been proposed that the direct stimulation of platelet production by this interleukin may have a compensatory eff ect in CBZ-induced thrombocytopenia 3 . Demonstration of the continuation of this compensatory eff ect during treatment with CBZ (or OXCBZ) may contribute towards explaining why the majority of patients administered these drugs do not develop thrombocytopenia. However, the MPV and PDW in the studied patients with platelet count of 150-400 x 10 9 /l were analogous to that obtained in healthy controls.
The usefulness in the clinical practice of complete blood count monitoring at initiation and during CBZ 
CBZ OXCBZ
treatment is a controversial issue 18, 21, 22 , but our results suggest that the platelet count monitoring in patients treated with CBZ and OXCBZ may be recommended.
